Aroa Biosurgery Ltd banner

Aroa Biosurgery Ltd
ASX:ARX

Watchlist Manager
Aroa Biosurgery Ltd Logo
Aroa Biosurgery Ltd
ASX:ARX
Watchlist
Price: 0.54 AUD
Market Cap: AU$186.8m

Wall St Price Targets

ARX Price Targets Summary
Aroa Biosurgery Ltd

Wall Street analysts forecast ARX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ARX is 1.09 AUD with a low forecast of 0.8 AUD and a high forecast of 1.42 AUD.

Lowest Forecast
Price Target
0.8 AUD
48% Upside
Average Forecast
Price Target
1.09 AUD
102% Upside
Highest Forecast
Price Target
1.42 AUD
162% Upside
Aroa Biosurgery Ltd Competitors:
Price Targets
JACK
Jack in the Box Inc
34% Upside
EOLS
Evolus Inc
71% Upside
TRIN
Trinity Capital Inc
2% Upside
FAST
Fastenal Co
0% Upside
PTCT
PTC Therapeutics Inc
44% Upside
NSIT
Insight Enterprises Inc
7% Upside

Revenue
Forecast

24% / Year
Past Growth
13% / Year
Estimated Growth
Estimates Accuracy
1%
Average Beat
24% / Year
Past Growth
13% / Year
Estimated Growth
Estimates Accuracy
1%
Average Beat

Over the last 7 years, the compound annual growth rate for Revenue has been 24%. The projected CAGR for the next 7 years is 13%.

Gross Profit
Forecast

27% / Year
Past Growth
15% / Year
Estimated Growth
Estimates Accuracy
1%
Average Beat
27% / Year
Past Growth
15% / Year
Estimated Growth
Estimates Accuracy
1%
Average Beat

Over the last 7 years, the compound annual growth rate for Gross Profit has been 27%. The projected CAGR for the next 3 years is 15%.

Operating Income
Forecast

32% / Year
Past Growth
32% / Year
Estimated Growth
Estimates Accuracy
18%
Average Beat
32% / Year
Past Growth
32% / Year
Estimated Growth
Estimates Accuracy
18%
Average Beat

Over the last 7 years, the compound annual growth rate for Operating Income has been 32%. The projected CAGR for the next 7 years is 32%.

Pre-Tax Income
Forecast

N/A
Past Growth
55% / Year
Estimated Growth
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
55% / Year
Estimated Growth
Estimates Accuracy
N/A
Average Beat/Miss

The compound annual growth rate for Pre-Tax Income over the next 2 years is 55%.

Net Income
Forecast

25% / Year
Past Growth
60% / Year
Estimated Growth
Estimates Accuracy
58%
Average Beat
25% / Year
Past Growth
60% / Year
Estimated Growth
Estimates Accuracy
58%
Average Beat

Over the last 7 years, the compound annual growth rate for Net Income has been 25%. The projected CAGR for the next 3 years is 60%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is ARX's stock price target?
Price Target
1.09 AUD

According to Wall Street analysts, the average 1-year price target for ARX is 1.09 AUD with a low forecast of 0.8 AUD and a high forecast of 1.42 AUD.

What is the Revenue forecast for Aroa Biosurgery Ltd?
Projected CAGR
13%

Over the last 7 years, the compound annual growth rate for Revenue has been 24%. The projected CAGR for the next 7 years is 13%.

What is the Gross Profit forecast for Aroa Biosurgery Ltd?
Projected CAGR
15%

Over the last 7 years, the compound annual growth rate for Gross Profit has been 27%. The projected CAGR for the next 3 years is 15%.

What is the Operating Income forecast for Aroa Biosurgery Ltd?
Projected CAGR
32%

Over the last 7 years, the compound annual growth rate for Operating Income has been 32%. The projected CAGR for the next 7 years is 32%.

What is the Pre-Tax Income forecast for Aroa Biosurgery Ltd?
Projected CAGR
55%

The compound annual growth rate for Pre-Tax Income over the next 2 years is 55%.

What is the Net Income forecast for Aroa Biosurgery Ltd?
Projected CAGR
60%

Over the last 7 years, the compound annual growth rate for Net Income has been 25%. The projected CAGR for the next 3 years is 60%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett